Shares of ValiRx plc (LON:VAL – Get Free Report) dropped 10% on Tuesday . The company traded as low as GBX 3.55 ($0.05) and last traded at GBX 3.60 ($0.05). Approximately 9,956,905 shares changed hands during mid-day trading, an increase of 695% from the average daily volume of 1,251,689 shares. The stock had previously closed at GBX 4 ($0.05).
ValiRx Price Performance
The firm has a 50-day simple moving average of GBX 3.40 and a 200-day simple moving average of GBX 5.57. The firm has a market capitalization of £4.00 million, a PE ratio of -104.33 and a beta of 0.63. The company has a debt-to-equity ratio of 0.73, a current ratio of 13.37 and a quick ratio of 1.27.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Read More
- Five stocks we like better than ValiRx
- Pros And Cons Of Monthly Dividend Stocks
- TJX Companies Can Hit New Highs; Double-Digit Upside to Follow
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- A Hidden Gem Retailer With 20% Upside
- What Investors Need to Know to Beat the Market
- Zoom Stock’s Earnings Volatility Picked Up a Lot of Buyers
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
